Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
2.31
|
2.42
|
2.35
|
2.31
|
2.51
|
2.35
|
|
|
273 560.87
|
650.00
|
2.21
|
2.50
|
2.21
|
2.11
|
2.37
|
2.31
|
|
|
199 398.09
|
638.00
|
2.09
|
2.39
|
2.20
|
2.08
|
2.25
|
2.17
|
|
|
120 830.29
|
473.00
|
2.15
|
2.28
|
2.08
|
2.04
|
2.33
|
2.17
|
|
|
233 842.27
|
617.00
|
1.98
|
2.18
|
2.12
|
2.03
|
2.3999
|
2.12
|
|
|
495 202.09
|
1 334.00
|
2.03
|
2.35
|
2.08
|
2.0499
|
2.25
|
2.13
|
|
|
180 686.82
|
598.00
|
1.75
|
2.25
|
2.15
|
2.02
|
2.2899
|
2.10
|
|
|
177 767.57
|
700.00
|
2.10
|
2.48
|
2.31
|
2.10
|
2.31
|
2.13
|
|
|
130 198.92
|
481.00
|
2.25
|
2.48
|
2.14
|
2.08
|
2.35
|
2.30
|
|
|
181 407.38
|
501.00
|
2.04
|
2.25
|
2.20
|
1.94
|
2.21
|
2.13
|
|
|
397 229.31
|
774.00
|
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a novel class of tissue-specific therapeutics in oncology and inflammation to treat inflammatory bowel disease, including ulcerative colitis and crohn's diseases. Immix Biopharma serves customers in the United States.